Register entry
- Registered sites
- 1
- Active NDC listings
- 6
- Live patents
- 38
- Exclusivities
- 3
- Countries
- 1
- Base
- United States
Sites
Registered establishments
1| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Rigel Pharmaceuticals, Inc. | 611 Gateway Boulevard, Suite 900, South San Francisco, California (CA) 94080, United States (USA) | Analytical testing | 3004865166967965468 |
Catalogue
Drug listings by form and route
66 active NDC listings: 6 human prescription drug. By marketing category: NDA 6.
| Dosage form | NDCs |
|---|---|
| capsule | 2 |
| tablet | 2 |
| tablet, film coated | 2 |
| Route | NDCs |
|---|---|
| oral | 6 |
| Labeller name on the listing | NDCs |
|---|---|
| rigel pharmaceuticals, inc. | 6 |
Exclusivity
Patents and exclusivities
38| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8652492 | TAVALISSEfostamatinib disodium | product | Nov 2028 |
| 8263122 | TAVALISSEfostamatinib disodium | product | Nov 2030 |
| 7449458 | TAVALISSEfostamatinib disodium | substance | Sept 2031 |
| 8771648 | TAVALISSEfostamatinib disodium | product | Jul 2032 |
| 8951504 | TAVALISSEfostamatinib disodium | use | Jul 2032 |
| 10414752 | REZLIDHIAolutasidenib | product | Sept 2035 |
| 10550098 | REZLIDHIAolutasidenib | product | Sept 2035 |
| 11498913 | REZLIDHIAolutasidenib | product | Sept 2035 |
| 12275715 | REZLIDHIAolutasidenib | substance, product | Sept 2035 |
| 9834539 | REZLIDHIAolutasidenib | substance, product | Sept 2035 |
| 10030005 | GAVRETOpralsetinib | substance, product | Nov 2036 |
| 12655128 | GAVRETOpralsetinib | substance, product | Nov 2036 |
| 10899742 | VEPPANUvepdegestrant | use | Dec 2037 |
| 11597720 | VEPPANUvepdegestrant | substance, product | Dec 2037 |
| 10647698 | VEPPANUvepdegestrant | substance, product | Jan 2038 |
| 11273160 | GAVRETOpralsetinib | use | Apr 2039 |
| 11872192 | GAVRETOpralsetinib | use | Apr 2039 |
| 11963958 | GAVRETOpralsetinib | use | Apr 2039 |
| 12539303 | GAVRETOpralsetinib | use | Apr 2039 |
| 10532047 | REZLIDHIAolutasidenib | substance | May 2039 |
| 10959994 | REZLIDHIAolutasidenib | product | May 2039 |
| 11013733 | REZLIDHIAolutasidenib | use | May 2039 |
| 11013734 | REZLIDHIAolutasidenib | use | May 2039 |
| 11376246 | REZLIDHIAolutasidenib | use | May 2039 |
| 11497743 | REZLIDHIAolutasidenib | use | May 2039 |
| 12053463 | REZLIDHIAolutasidenib | substance, product | May 2039 |
| 11738018 | REZLIDHIAolutasidenib | use | Jul 2039 |
| 11723905 | REZLIDHIAolutasidenib | product | Nov 2039 |
| 12448366 | GAVRETOpralsetinib | substance | Jul 2042 |
| 12692251 | GAVRETOpralsetinib | product | Apr 2043 |
| Product | Exclusivity | Until |
|---|---|---|
| GAVRETOPRALSETINIB | ODE-340 Orphan drug | Dec 2027 |
| REZLIDHIAOLUTASIDENIB | ODE-413 Orphan drug | Dec 2029 |
| VEPPANUVEPDEGESTRANT | NCE New chemical entity | May 2031 |
Catalogue
Marketed products
6| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Gavreto | Pralsetinib | capsule, oral | 71332-006NDA |
| REZLIDHIA | olutasidenib | capsule, oral | 71332-005NDA |
| TAVALISSE | FOSTAMATINIB | tablet, oral | 71332-001NDA |
| TAVALISSE | FOSTAMATINIB | tablet, oral | 71332-002NDA |
| VEPPANU | vepdegestrant | tablet, film coated, oral | 71332-007NDA |
| VEPPANU | vepdegestrant | tablet, film coated, oral | 71332-008NDA |
Neighbours
Registered in the same town
1- Genentech, Inc.South San Francisco, CA
Compare
Comparable companies in United States
- Rising Pharma Holdings, Inc.1 site · 532 NDC
- ANI Pharmaceuticals, Inc.1 site · 299 NDC
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.1 site · 273 NDC
- Lannett Company, LLC1 site · 190 NDC
- CHATTEM, INC.1 site · 153 NDC
- PAI Holdings, LLC1 site · 146 NDC
- Allegiant Health1 site · 113 NDC
- Healthcare Sales and Service, LLC1 site · 105 NDC
- Civica, Inc. dba CivicaRx1 site · 103 NDC
- Leading Pharma, LLC1 site · 82 NDC
Enquiry
Common questions
- Is Rigel Pharmaceuticals, Inc. FDA approved?
- Rigel Pharmaceuticals, Inc. holds 1 FDA-registered establishment in the United States. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Rigel Pharmaceuticals, Inc.'s registered sites?
- The FDA register lists South San Francisco, CA. Registered operations: analytical testing.
- What drugs does Rigel Pharmaceuticals, Inc. make?
- 6 products are listed under Rigel Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as capsule; tablet; tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.